Your browser doesn't support javascript.
loading
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
Rundquist, Sara; Sachs, Michael C; Eriksson, Carl; Olén, Ola; Montgomery, Scott; Halfvarson, Jonas.
Afiliação
  • Rundquist S; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Sachs MC; Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
  • Eriksson C; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Olén O; Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
  • Montgomery S; Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
  • Halfvarson J; Sachs' Children and Youth Hospital, Department of Clinical Science and Education, Stockholm South General Hospital, Karolinska Institute, Stockholm, Sweden.
Aliment Pharmacol Ther ; 53(9): 1046-1047, 2021 05.
Article em En | MEDLINE | ID: mdl-33831234
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Preparações Farmacêuticas / Doenças Inflamatórias Intestinais Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Preparações Farmacêuticas / Doenças Inflamatórias Intestinais Idioma: En Ano de publicação: 2021 Tipo de documento: Article